NASDAQ OMX

Aino Health AB (publ): The Offer in Aino Health AB (publ) heavily oversubscribed

9.12.2016 08:30 | NASDAQ OMX

Dela

PRESS RELEASE
December 9, 2016

NOT FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, TO NEWS DISTRIBUTORS IN THE UNITED STATES, OR FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION OR PUBLICATION WOULD NOT BE ALLOWED BY APPLICABLE LAW.
  
Aino Health AB (publ) ("Aino Health" or the "Company") has completed the Offer to the market to subscribe for shares in the Company for a total of 53.8 MSEK (the "Offer"), distributed on a share issue of 46.8 MSEK (the "Share Issue") and an Over-allotment of existing shares of 7.0 MSEK for stabilization activities (the "Over-allotment"). The Over-allotment including stabilization of the share price during 30 calendar days may imply that Aino Health will receive an addition of 7.0 MSEK through a share issue included in the Over-allotment option directed to Erik Penser Bank AB, after which the Company would receive up to 48.8 MSEK.  

The Offer attracted strong interest and was subscribed to about 206 percent, equivalent to 2.1 times the Offer. Due to the strong interest shares have been allocated to around 1 100 new shareholders among almost 4 000 applicants. First day of trading Aino Health's shares is scheduled for Friday December 16, 2016.

November 27, 2016, the Board of Directors in Aino Health published the decision to apply for listing of the Company's shares on Nasdaq First North, and in connection with the listing the Board of Directors decided to diversify the ownership through a Share Issue according to the Offer. The Offer consists of 1,800,000 newly issued shares and an Over-allotment of 270,000 existing shares as a part of the stabilization of the share price during 30 calendar days. The Company may receive an addition of 270,000 shares through the Over-allotment option directed to Erik Penser Bank as a part of the agreed stabilization of the share price.

The number of shares will increase from 3,622,770 to 5,422,770 through the Share Issue and up to 5,692,770 shares if the Over-allotment is fully exercised. The dilution for existing shareholders amounts to 33.2 percent and to a maximum of 36.2 percent if the Over-allotment option is fully exercised.

The Offer implies that the Company will be added around 1 100 new shareholders, after which the total number of shareholders will amount to approximately 1 200. The Company will meet the share distribution requirements on Nasdaq First North and the first day of trading is scheduled for Friday December 16, 2016.

The subscription period for the Offer expired on Thursday, December 8, 2016. A number of institutional partners and private investors have, before the initiated subscription period, undertaken to subscribe for shares in the Share Issue corresponding to approximately 31.9 MSEK, or about 86 percent of the Share Issue.

The Board of Directors in Aino Health has, in consultation with Erik Penser Bank, decided on the allotment of shares in the Offer, in which the objective has been to achieve a good distribution of the share to enable a regular and liquid trading on Nasdaq First North as well as achieving a desired strategic ownership base. The allotment decision will be obtained in the form of a contract note. Information will not be sent to those who have not been allotted shares.

After the Offer has been registered at the Swedish Companies Registration Office the total number of shares in Aino Health will increase by 1,800,000 shares from 3,622,770 shares to 5,422,770 shares. The share capital will increase by 4,500,000 SEK to 13,556,925 SEK. If the Over-allotment option is fully exercised, this implies an additional increase of 270,000 shares and an increase of the share capital of 675,000 SEK to 14,231,925 SEK.

"We are very pleased with the great interest we have had in Aino Health's IPO. While we have secured capital for our expansion into Europe with focus on Sweden and Germany as the first countries, we have received a large number of new shareholders. We are very happy for this and the legitimacy that our listing gives in various customer contacts", says Jyrki Eklund, CEO of Aino Health

Advisers
Erik Penser AB is the financial advisor and Advokatfirman Lindahl KB is the legal adviser in the Offer and listing on Nasdaq First North. Erik Penser AB is Certified Adviser to the Company.

Important information
Publication and distribution of this press release may in certain jurisdictions be restricted by law and persons in those jurisdictions where this press release has been published or distributed should inform themselves about and follow such restrictions. The information in this press release is not an offer to acquire, subscribe for or otherwise trade in shares or another security in Aino Health.

This press release may not be released, published or distributed, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa or another country where such action requires further measures in addition to what follows from Swedish law or where this would contravene with laws or regulations of that country. The information in this press release may not be forwarded, reproduced or disclosed in ways that conflict with such restrictions. Omission to follow this instruction may constitute a violation of the United States Securities Act of 1933 (the "Securities Act") in its present terms or applicable laws in other jurisdictions.

This information is such information that Aino Health AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at December 9 CET on 8:30 2016.

F or more information, please contact:
Jyrki Eklund, CEO
Phone: +358 40 042 4221
E-mail: jyrki.eklund@ainohealth.com

Cecilia Hollerup, Chairman of the Board of Directors
Phone: +46 70 829 33 36
E-mail: cecilia.hollerup@holleruppartners.se

About Aino Health
Aino Health operates within Corporate Health Management. The company has developed a complete system of IT-based services with a focus to improve corporate health and reduce sickness absence levels in private and public organizations.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Aino Health AB (publ) via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste pressmeddelandena från NASDAQ OMX

Promethean Opens New Global Headquarters in Seattle18.8.2017 18:38Pressmeddelande

Seattle, Wash., Aug. 18, 2017 (GLOBE NEWSWIRE) -- PrometheanTM, a global education technology company, announced today the opening of its new global headquarters in Seattle, Wash. Promethean's office in Atlanta, Ga. will continue to serve as the hub for the Americas markets, and the Blackburn, U.K. office will continue to carry on as the hub for the EMEA markets and parts of Asia.  Promethean is one of the leading brands in the international education technology market with more than 20 years of experience in the K-12 classroom. Its solutions are in more than 50,000 schools and institutions in 154 countries. "As traditional pedagogy continues to move towards immersive learning, it's important for Promethean to lead innovation in education with the latest technology," said Vin Riera, CEO of Promethean. "Seattle is a global technology hub, and establishing Promethean's global headquarters there increases opportunities for new business models, concepts

Hminers Disrupts the Cryptocurrency Market with Powerful, Multi-Algorithm Mining Rigs18.8.2017 11:00Pressmeddelande

Hminers continues to hit the headlines in the rapidly expanding global market for cryptocurrency. The Miami-based company has recently introduced three extremely powerful, multi-algorithm mining rigs that have been designed to provide maximum hash rate with minimum power consumption. MIAMI, Aug. 18, 2017 (GLOBE NEWSWIRE) -- In their relentless efforts to deliver state-of-the-art products related to cryptocurrency, Hminers has recently launched three brilliantly designed bitcoin mining rigs. The unique features and capabilities of the company's new H2U Miner, H4U Miner, and Rack Equipped with 5 x H4U have already grabbed the attention of the cryptocurrency enthusiasts and experts around the world. An organization with a rich tradition, Hminers (www.hminers.com) is recognized in the industry as the creator of the first ever 10 nm ASIC Chip in the world. Cryptocurrency mining is the process of generating new cryptocurrency that requires a pot

Nasdaq Welcomes I-AM Capital Acquisition Company (Nasdaq: IAMXU) to The Nasdaq Stock Market17.8.2017 18:50Pressmeddelande

NEW YORK, Aug. 17, 2017 (GLOBE NEWSWIRE) -- I-AM Capital Acquisition Company (Nasdaq:IAMXU), a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, celebrated its initial public offering (IPO) on The Nasdaq Stock Market.  I-AM Capital's founders, Chief Executive Officer F. Jacob Cherian and Chief Financial Officer Suhel Kanuga, have been focused on investing into India over the last decade, with the distinction of completing the first listed-SPAC investment in India. "Through our keen focus and unique accomplishments in India over the last decade, we have seen our investment thesis bear fruit: India's prominence and rise on the world stage, its distinction as being one of the fastest growing major economies of the world, and its strong vibrant consumer demographics. We believe these factors are aligning well now,

Tetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency17.8.2017 14:30Pressmeddelande

WATERTOWN, Mass., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug- resistant (MDR) infections, today announced that the Marketing Authorization Application (MAA) for IV eravacycline for the treatment of complicated intra-abdominal infections (cIAI) has been submitted and was validated by the European Medicines Agency (EMA). Eravacycline is a novel, fully-synthetic fluorocycline antibiotic being developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens. The MAA filing is based on data from the phase 3 IGNITE1 clinical trial in which eravacycline was well tolerated and demonstrated statistical non-inferiority to ertapenem using the primary endpoint of clinical response at the test-of-cure (TOC) visit. "The MAA filing represents a significant milestone for Tetraphase as it is our

RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules17.8.2017 13:00Pressmeddelande

RedHill was granted the exclusive rights to promote Esomeprazole Strontium Delayed-Release (DR) Capsules to gastroenterologists in certain U.S. territories Esomeprazole Strontium DR Capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor (PPI), indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal (GI) conditions   RedHill expects to initiate the U.S. promotion of Esomeprazole Strontium  DR Capsules 49.3 mg  in the coming weeks   Esomeprazole Strontium  DR Capsules 49.3 mg  will be the third commercial GI product to be promoted by RedHill in the U.S.    RedHill's GI-focused sales force currently promotes two GI s

Brand Industrial Services Announces Agreement to Acquire Venko Groep BV16.8.2017 19:40Pressmeddelande

Complementary core strengths provide broader range of services for customers KENNESAW, GA, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Brand Industrial Services, known as BrandSafway, has signed an agreement to acquire Venko Groep BV, a portfolio company of Mentha Capital. Venko will become a part of the Brand Energy & Infrastructure Services (Brand) group. "We are very pleased to announce the agreement with Venko," said Bill Hayes, President and CEO of BrandSafway. "Our combined customers in Europe will benefit from a broader range of solutions and greater depth of expertise in access, insulation and coatings. Bringing Venko's highly specialized knowledge in coatings to BrandSafway will provide the expertise we need to expand our services in the offshore market worldwide." Based in the Netherlands, with a focus on operations in the North Sea area, Venko is a leading offshore and onshore coatings maintenance provid

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum